Mkrtumyan A, et al. - A multicenter, double-blind, placebo-controlled, randomized clinical trial was performed to investigate the efficacy of Subetta as an add-on to insulin therapy in patients with type 1 diabetes mellitus (T1DM). For the purpose of this investigation, the researchers involved an aggregate of 144 randomized patients with poor glycemic control in basal-bolus insulin regime in intention-to-treat analysis in Subetta add-on therapy or placebo (n = 72 in both groups). They recorded hemoglobin A1c (HbA1c), fasting plasma glucose (FPG), basal and prandial insulin doses, number of hypoglycemia episodes confirmed by self-monitoring of blood glucose for 36 weeks. In patients with T1DM, Subetta add-on therapy boosting insulin activity and improving glycemic control was proved to be beneficial.